DalsnaFinance › Analyst accuracy › Rothschild & Co Redburn › MRNA target
Rothschild Redburn downgrades Moderna stock on valuation concerns
Rothschild Redburn downgraded Moderna stock to Sell from Neutral and raised its price target to $81 from $40
A fact about what Rothschild & Co Redburn published, as reported by Investing.com, not a recommendation from Dalsna Finance; Rothschild & Co Redburn is not affiliated with this site.
Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.